| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
|
N Engl J Med
|
2006
|
34.52
|
|
2
|
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
|
JAMA
|
2003
|
12.35
|
|
3
|
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
|
J Clin Oncol
|
2004
|
8.83
|
|
4
|
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
|
J Clin Oncol
|
2004
|
8.15
|
|
5
|
Lung cancer in never smokers--a different disease.
|
Nat Rev Cancer
|
2007
|
6.41
|
|
6
|
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
4.95
|
|
7
|
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
4.79
|
|
8
|
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
|
J Natl Cancer Inst
|
2007
|
4.07
|
|
9
|
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
|
J Clin Oncol
|
2008
|
3.83
|
|
10
|
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.
|
J Clin Oncol
|
2011
|
3.21
|
|
11
|
Recent clinical advances in lung cancer management.
|
J Clin Oncol
|
2014
|
2.82
|
|
12
|
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.
|
Clin Cancer Res
|
2008
|
2.81
|
|
13
|
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
|
J Clin Oncol
|
2011
|
2.69
|
|
14
|
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
|
J Clin Oncol
|
2004
|
2.16
|
|
15
|
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
|
J Clin Oncol
|
2010
|
1.93
|
|
16
|
New molecularly targeted therapies for lung cancer.
|
J Clin Invest
|
2007
|
1.86
|
|
17
|
Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data.
|
J Clin Oncol
|
2005
|
1.85
|
|
18
|
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2006
|
1.84
|
|
19
|
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.
|
J Clin Oncol
|
2012
|
1.72
|
|
20
|
Perceived stigma, self-blame, and adjustment among lung, breast and prostate cancer patients.
|
Psychol Health
|
2009
|
1.59
|
|
21
|
EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer.
|
J Thorac Oncol
|
2006
|
1.57
|
|
22
|
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
|
J Clin Oncol
|
2009
|
1.54
|
|
23
|
Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.
|
J Thorac Cardiovasc Surg
|
2004
|
1.52
|
|
24
|
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.
|
Clin Cancer Res
|
2011
|
1.52
|
|
25
|
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
|
J Thorac Oncol
|
2009
|
1.45
|
|
26
|
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
|
Clin Lung Cancer
|
2012
|
1.40
|
|
27
|
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).
|
J Thorac Oncol
|
2007
|
1.39
|
|
28
|
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.
|
J Clin Oncol
|
2003
|
1.33
|
|
29
|
Stigma among patients with lung cancer: a patient-reported measurement model.
|
Psychooncology
|
2013
|
1.30
|
|
30
|
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
|
J Clin Oncol
|
2009
|
1.27
|
|
31
|
Assessment of guilt and shame in patients with non-small-cell lung cancer compared with patients with breast and prostate cancer.
|
Clin Lung Cancer
|
2008
|
1.26
|
|
32
|
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
|
J Clin Oncol
|
2005
|
1.19
|
|
33
|
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
|
J Thorac Oncol
|
2010
|
1.17
|
|
34
|
Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea.
|
J Clin Oncol
|
2013
|
1.12
|
|
35
|
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
|
Lung Cancer
|
2008
|
1.11
|
|
36
|
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
|
Clin Pharmacol Ther
|
2002
|
1.10
|
|
37
|
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2011
|
1.09
|
|
38
|
Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
|
J Thorac Oncol
|
2012
|
1.09
|
|
39
|
Differences in primary care clinicians' approach to non-small cell lung cancer patients compared with breast cancer.
|
J Thorac Oncol
|
2007
|
1.08
|
|
40
|
Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial.
|
Clin Lung Cancer
|
2006
|
1.06
|
|
41
|
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
|
Clin Cancer Res
|
2007
|
1.05
|
|
42
|
Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations.
|
J Thorac Oncol
|
2014
|
1.04
|
|
43
|
A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.
|
Invest New Drugs
|
2009
|
1.03
|
|
44
|
Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.
|
J Thorac Oncol
|
2013
|
1.03
|
|
45
|
Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
|
Cancer
|
2006
|
1.03
|
|
46
|
An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trial.
|
Cancer
|
2013
|
1.02
|
|
47
|
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594.
|
J Thorac Oncol
|
2006
|
1.02
|
|
48
|
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
|
Clin Cancer Res
|
2007
|
1.01
|
|
49
|
Angiogenesis inhibitors in the treatment of lung cancer.
|
Crit Rev Oncol Hematol
|
2007
|
0.98
|
|
50
|
Addressing the current challenges of non-small-cell lung cancer clinical trial accrual.
|
Clin Lung Cancer
|
2008
|
0.97
|
|
51
|
Using liquid crystals to report membrane proteins captured by affinity microcontact printing from cell lysates and membrane extracts.
|
J Am Chem Soc
|
2005
|
0.96
|
|
52
|
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
|
J Thorac Oncol
|
2012
|
0.93
|
|
53
|
Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504).
|
J Clin Oncol
|
2011
|
0.91
|
|
54
|
Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer.
|
J Support Oncol
|
2005
|
0.91
|
|
55
|
Novel therapies for the treatment of non-small cell lung cancer.
|
Cancer Chemother Biol Response Modif
|
2002
|
0.91
|
|
56
|
The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.
|
Oncol Rep
|
2011
|
0.90
|
|
57
|
Clinician perceptions of care difficulty, quality of life, and symptom reports for lung cancer patients: an analysis from the Symptom Outcomes and Practice patterns (SOAPP) study.
|
J Thorac Oncol
|
2013
|
0.90
|
|
58
|
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
|
J Thorac Oncol
|
2012
|
0.89
|
|
59
|
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
|
Cancer Chemother Pharmacol
|
2009
|
0.89
|
|
60
|
Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590.
|
Lung Cancer
|
2007
|
0.89
|
|
61
|
Novel agents in the treatment of lung cancer: conference summary statement.
|
Clin Cancer Res
|
2004
|
0.88
|
|
62
|
Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study.
|
J Thorac Oncol
|
2010
|
0.88
|
|
63
|
Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.
|
Oncologist
|
2005
|
0.87
|
|
64
|
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2.
|
Clin Lung Cancer
|
2006
|
0.86
|
|
65
|
Novel therapies for lung cancer.
|
Surg Oncol
|
2002
|
0.85
|
|
66
|
Predictive and prognostic factors for non-small cell lung cancer--potholes in the road to the promised land.
|
J Natl Cancer Inst
|
2011
|
0.85
|
|
67
|
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2006
|
0.85
|
|
68
|
A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
|
Clin Cancer Res
|
2003
|
0.84
|
|
69
|
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.
|
Lung Cancer
|
2003
|
0.83
|
|
70
|
[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].
|
Zhongguo Fei Ai Za Zhi
|
2010
|
0.82
|
|
71
|
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.
|
Am J Clin Oncol
|
2016
|
0.82
|
|
72
|
Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599.
|
J Thorac Oncol
|
2011
|
0.81
|
|
73
|
Systemic treatment of advanced non-small cell lung cancer.
|
Drugs Today (Barc)
|
2004
|
0.81
|
|
74
|
Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors.
|
Cancer Treat Rev
|
2012
|
0.81
|
|
75
|
Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement.
|
Clin Cancer Res
|
2005
|
0.79
|
|
76
|
DNA methylation biomarkers to assess therapy and chemoprevention for non-small cell lung cancer.
|
Nutr Rev
|
2008
|
0.79
|
|
77
|
Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
|
Invest New Drugs
|
2013
|
0.78
|
|
78
|
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.78
|
|
79
|
Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be better after all.
|
J Clin Oncol
|
2009
|
0.78
|
|
80
|
Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).
|
J Thorac Oncol
|
2013
|
0.78
|
|
81
|
Noninvasive monitoring of tumors.
|
N Engl J Med
|
2008
|
0.78
|
|
82
|
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
|
Lung Cancer
|
2013
|
0.78
|
|
83
|
Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy.
|
Expert Rev Anticancer Ther
|
2002
|
0.78
|
|
84
|
Chemotherapy for advanced non-small cell lung cancer.
|
Hematol Oncol Clin North Am
|
2004
|
0.77
|
|
85
|
Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).
|
Cancer Chemother Pharmacol
|
2014
|
0.77
|
|
86
|
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
|
Clin Lung Cancer
|
2009
|
0.77
|
|
87
|
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
|
Clin Lung Cancer
|
2005
|
0.77
|
|
88
|
Phase I study of docetaxel and topotecan in patients with advanced malignancies.
|
J Oncol Pharm Pract
|
2005
|
0.77
|
|
89
|
Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.
|
Clin Lung Cancer
|
2009
|
0.75
|
|
90
|
Putting lung cancer clinical trials into perspective.
|
Oncology (Williston Park)
|
2011
|
0.75
|
|
91
|
Can current treatments for advanced non-small-cell lung cancer be improved?
|
JAMA
|
2004
|
0.75
|
|
92
|
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
|
J Thorac Oncol
|
2008
|
0.75
|
|
93
|
Platin or no platin? That is the question.
|
J Clin Oncol
|
2003
|
0.75
|
|
94
|
Adjuvant therapy in the treatment of non-small-cell lung cancer.
|
Clin Lung Cancer
|
2002
|
0.75
|